NASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Price, News & Analysis $13.67 +0.01 (+0.07%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$14.12 +0.45 (+3.26%) As of 05/22/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Viridian Therapeutics Stock (NASDAQ:VRDN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Viridian Therapeutics alerts:Sign Up Key Stats Today's Range$13.38▼$13.8750-Day Range$11.02▼$15.4652-Week Range$9.90▼$27.20Volume568,146 shsAverage Volume1.19 million shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$36.70Consensus RatingModerate Buy Company OverviewViridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.Read More… Viridian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreVRDN MarketRank™: Viridian Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 520th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingViridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageViridian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viridian Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Viridian Therapeutics are expected to decrease in the coming year, from ($4.03) to ($4.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.40% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 8.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.40% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Viridian Therapeutics has recently decreased by 8.33%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.45 News SentimentViridian Therapeutics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Viridian Therapeutics this week, compared to 5 articles on an average week.Search Interest3 people have searched for VRDN on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.58% of the stock of Viridian Therapeutics is held by insiders.Read more about Viridian Therapeutics' insider trading history. Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Stock News HeadlinesViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalystsMay 21 at 8:57 PM | investing.comViridian Therapeutics (VRDN) to Release Earnings on WednesdayMay 13, 2025 | americanbankingnews.comElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.May 23, 2025 | GoldenCrest Metals (Ad)Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)May 7, 2025 | finance.yahoo.comViridian Therapeutics shares fall as Q1 loss narrows, revenue beatsMay 6, 2025 | in.investing.comViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comViridian Therapeutics appoints Ajer to its board of directorsApril 8, 2025 | markets.businessinsider.comViridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsApril 7, 2025 | finance.yahoo.comSee More Headlines VRDN Stock Analysis - Frequently Asked Questions How have VRDN shares performed this year? Viridian Therapeutics' stock was trading at $19.17 at the beginning of 2025. Since then, VRDN shares have decreased by 28.7% and is now trading at $13.67. View the best growth stocks for 2025 here. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its earnings results on Tuesday, May, 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The business's revenue was up .0% compared to the same quarter last year. Who are Viridian Therapeutics' major shareholders? Viridian Therapeutics' top institutional investors include Vanguard Group Inc. (5.59%), Paradigm Biocapital Advisors LP (2.57%), Maverick Capital Ltd. (2.53%) and Alliancebernstein L.P. (2.48%). Insiders that own company stock include Fairmount Funds Management Llc, Jonathan Violin, Scott Dunseth Myers, Lara Meisner, Stephen F Mahoney, Thomas W Beetham and Barrett Katz. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viridian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings5/06/2025Today5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:VRDN CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$36.70 High Stock Price Target$61.00 Low Stock Price Target$27.00 Potential Upside/Downside+168.5%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-237,730,000.00 Net Margins-85,127.16% Pretax Margin-85,127.16% Return on Equity-70.12% Return on Assets-41.49% Debt Debt-to-Equity Ratio0.04 Current Ratio18.55 Quick Ratio18.55 Sales & Book Value Annual Sales$302,000.00 Price / Sales3,693.25 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book3.05Miscellaneous Outstanding Shares81,592,000Free Float78,698,000Market Cap$1.12 billion OptionableOptionable Beta0.57 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:VRDN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.